Earnings Report - Abbott Laboratories is set to release its fourth-quarter earnings on January 22, with expected earnings of $1.49 per share, an increase from $1.34 per share in the same period last year [1] - The consensus estimate for Abbott's quarterly revenue is $11.8 billion, up from $10.97 billion reported last year [1] Recent Developments - On January 20, Abbott received CE Mark approval for the TactiFlex™ Duo Ablation Catheter, aimed at treating patients with abnormal heart rhythms [2] - Following this news, Abbott's shares fell by 0.3%, closing at $120.73 [2] Analyst Ratings - Bernstein analyst Lee Hambright maintained an Outperform rating and raised the price target from $150 to $154 [3] - Barclays analyst Matt Miksic maintained an Overweight rating and increased the price target from $162 to $169 [3] - BTIG analyst Marie Thibault maintained a Buy rating with a price target of $145 [3] - Raymond James analyst Jayson Bedford maintained an Outperform rating and raised the price target from $141 to $146 [3] - Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating but reduced the price target from $144 to $142 [3]

1 TactiFlex Duo Supported by Strong Data CE Mark approval for the TactiFlex Duo Ablation Catheter was supported by data from Abbott's FOCALFLEX CE Mark study, a global clinical trial conducted at centers in the European Union, United Kingdom and Australia. The trial showed that TactiFlex Duo demonstrated clinically meaningful performance in the safety and effectiveness of treating patients with AFib. 2,3 Approximately eight million Europeans over the age of 65 are living with AFib, a number expected to doub ...